Phase II open-label study of M200 [volociximab] in patients with metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2012
At a glance
- Drugs Volociximab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 27 Dec 2007 Status change from ongoing to discontinued.
- 13 Aug 2007 Status changed from recruiting to in progress.
- 19 Sep 2005 New trial record.